Abstract
A neuroprotective effect of lithium in amyotrophic lateral sclerosis (ALS) has been recently reported. We performed a multicenter trial with lithium carbonate to assess its tolerability, safety, and efficacy in patients with ALS, comparing 2 different target blood levels (0.4-0.8 mEq/L, therapeutic group [TG], vs 0.2-0.4 mEq/L, subtherapeutic group [STG]).
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | 619-625 |
| Numero di pagine | 7 |
| Rivista | Neurology |
| Volume | 75 |
| Numero di pubblicazione | 7 |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2010 |
Keywords
- Adolescent
- Adult
- Aged
- Amyotrophic Lateral Sclerosis
- Dose-Response Relationship
- Drug
- Enzyme Inhibitors
- Female
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Lithium Carbonate
- Male
- Middle Aged
- Retrospective Studies
- Single-Blind Method
- Time Factors
- Treatment Outcome
- Young Adult
Fingerprint
Entra nei temi di ricerca di 'Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver